Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52)

European Journal of Haematology

Volumn 58, Issue 1, 1997, Pages 5-13

  Osterborg A ^a   Werner, A ^a   Halapi, E ^a   Lundin, J ^a   Harmenberg, U ^a   Wigzell, H ^b   Mellstedt, H ^a,c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Campath 1H; CD52; clonal; monoclonal antibody; T cells

Indexed keywords

ALEMTUZUMAB; CD52 ANTIGEN; CD8 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CELL CLONE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0031022899     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1997.tb01403.x     Document Type: Article

References (33)

1. RIECHMANN L, CLARK M, WALDMANN H, WINTER G. Reshaping human antibodies for therapy. Nature 1988:332: 323-327.
2. ISAACS JD. The antiglobulin response to therapeutic antibodies. Semin Immunol 1992:2:449-456.
3. HALE G, XIA MQ, TIGHE HP, DYER MJS, WALDMANN H. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990: 35:118-127.
4. W52 antigen expression in non-Hodgkin's lymphomas. J Clin Pathol 1994:47:313-317.
5. HALE G, HOANG T, PROSPERO T, WATT SM, WALDMANN H. Removal of T cells from bone marrow for transplantation: comparison of rat monoclonal anti-lymphocyte antibodies of different isotypes. Mol Biol Med 1983:1:305-311.
6. HALE G, DYER MJS, CLARK MR, et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody Campath-1H. Lancet 1988:1:1394-1399.
7. STEPLEWSKI Z, LUBECK MD, KOPROWSKI H. Human macrophages armed with murine IgG2a anti-tumor immunoglobulins destroy human cancer cells. Science 1983:221: 865-867.
8. HALE G, CLARK M, WALDMANN H. Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes. J Immunol 1985:134:3056-3061.
9. W52) antigen. Mol Immunol 1993:30:1089-1096.
10. TRAUTH BC, KLAS C, PETERS AMJ, et al. Monoclonal antibody mediated tumor regression by induction of apoptosis. Science 1989:245:301-305.
11. BURNET FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970:13:1-27.
12. JERNE NK. Towards a network theory of the immune system. Ann Immunol (Inst Pasteur), 1974:125C:373-389.
13. CARBONE PP, KAPLAN HS, MUSSHOFF K, SMITHERS DW, TUBIANA M. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971:311:860-861.
14. RAI KR, SAWITSKY A, CRONKITE EP, CHANANA AD, LEVY RN, PASTERNACK BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975:46:219-234.
15. HULTMAN T, STAHL S, HORNES E, UHLÉN M. Direct solid phase sequencing of genomic and plasmid DNA using magnetic beads as solid support. Nucleic Acids Res 1989:17:4937-4946.
16. PANNETIER C, COCHET M, DARCHE S, CASROUGE A, ZöLLER M, KOURILSKY P. The sizes of the CDR3 hypervariable regions of the murine T-cell receptor β chains vary as a function of the recombined germ-line segments. Proc Natl Acad Sci USA 1993:90:4319-4323.
17. JANSON CH, GRUNEWALD J, ÖSTERBORG A, et al. Predominant T cell receptor V gene usage in patient with abnormal clones of B cells. Blood 1991:77:1776-1780.
18. ISAACS JD, WATTS RA, HAZLEMAN BL, et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992:340: 748-752.
19. GAZITT Y, OR M, MUMCUOGLU M, SLAVIN S. Monoclonal rat anti-human lymphocyte antibody Campath-1 binds to T and B lymphocytes but effectively lyses only T cells. Bone Marrow Trans 1987: 2:427-433.
20. LIM SH, DAVEY G, MARCUS R. Differential response in a patient treated with Campath-1H monoclonal antibody for refractory non-Hodgkin lymphoma. Lancet 1993:341: 432-433.
21. DYER MJS, HALE G, HAYHOE F, WALDMANN H. Effects of Campath-1 antibodies in vivo in patients with lymphoid malignancies: influence by antibody isotype. Blood 1989:73: 1431-1439.
22. SHETYE J, FRÖDIN J-E, CHRISTENSSON B, et al. Immunohistochemical monitoring of metastatic colorectal carcinoma in patients treated with monoclonal antibodies (mAb 17-1A). Cancer Immunol Immunother 1988:27:154-162.
23. HERTENSTEIN B, WAGNER B, BUNJES D, et al. Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma. Blood 1995: 86:1487-1492.
24. SHU S, KRINOCK RA, MATSUMURA T, et al. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation ot tumorspecific effector T cells. J Immunol 1994:152:1277-1288.
25. + T cells. J Exp Med 1995:181:1863-1868.
26. PUISIEUX I, EVEN J, PANNETIER C, JOTEREAU F, FAVROT M, KOURILSKY P. Oligoclonality of tumor-infiltrating lymphocytes from human melanomas. J Immunol 1994:153: 2807-2818.
27. + sarcoidosis patients. Mol Med 1995:1:1-10.
28. FAGERBERG J, HJELM A-L, RAGNHAMMAR P, FRÖDIN J-E, WIGZELL H, MELLSTEDT H. Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. Cancer Res 1995:55: 1824-1827.
29. WEN T, MELLSTEDT H, JONDAL M. Presence of clonal T cell populations in chronic B lymphocytic leukemia and smoldering myeloma. J Exp Med 1990:171: 659-666.
30. FARACE F, ORLANDUCCI F, DIETRICH P-Y, et al. T cell repertoire in patients with B chronic lymphocytic leukemia. Evidence for multiple in vivo T cell clonal expansions. J Immunol 1994:153: 4281-4290.
31. + ovarian cancers. J Immunol 1994:152:4993-4999.
32. YAMAMOTO K, MASUKO K, TAKAHASHI S, et al. Accumulation of distinct T cell clonotypes in human solid tumors. J Immunol 1995:154:1804-1809.
33. SENSI ML, PARMIANI G. Analyses of TCR usage in human tumors: a new tool for assessing tumor specific immune responses. Immunol Today 1995:16:588-595.